Category: 226942-29-6

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To solid 2,4- dichloropyrimidine (184.8 mg, 1.240 mmol) was slowly added a solution of 6-bromo- 1,2,3,4-tetrahydroisoquinoline (262 mg, 1.235 mmol) and triethylamine (390 mu, 2.80 mmol) in NMP (3 mL). The reaction was stirred at rt for 20 min then heated to 80 C for 1 h 45 min. The reaction was then treated with morpholine (500 mu, 5.74 mmol) and heated to 100 C for 18 h. The crude reaction was purified via reverse phase Prep HPLC to afford 4-(4-(6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-2-yl)mophiholine, 386 mg (83%). LCMS (M+l) = 375.1, 377.1. NMR (500 MHz, CDCb) delta 8.02 – 7.98 (m, 1H), 7.38 – 7.34 (m, 2H), 7.08 (d, J=8.7 Hz, lH), 5.96 (d, J=6.0 Hz, 1H), 4.67 (s, 2H), 3.86 – 3.76 (m, 10H), 2.92 (t, J=5.8 Hz, 2H).

226942-29-6, As the paragraph descriping shows that 226942-29-6 is playing an increasingly important role.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.

General procedure: The mixtures of 4-(bromomethyl)benzoic acid (200 mg, 0.93 mmol, 1 equiv.) and correspondingtetrahydroisoquinolines A (1.86 mmol, 2 equiv.) in 8 mL anhydrous THF were refluxed for 8 h,and the progress of the reaction was followed using TLC. After completion of the reaction, the reactionmixture was cooled to room temperature and the solvent was removed under vacuo. The resultantsolid was dissolved in 1N NaOH (20 mL) and then extracted with CH2Cl2 (3 20 mL). The aqueouslayer was acidified to pH = 1 using 10% HCl (20 mL), resulting in precipitation of the final compounds., 226942-29-6

As the paragraph descriping shows that 226942-29-6 is playing an increasingly important role.

Reference£º
Article; Jiang, Cheng-Shi; Ge, Yong-Xi; Cheng, Zhi-Qiang; Wang, Yin-Yin; Tao, Hong-Rui; Zhu, Kongkai; Zhang, Hua; Molecules; vol. 24; 14; (2019);,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,226942-29-6

General procedure: To the solution of amine (2a-10a) (1mmol) in DCM (5mL), triethylamine (2mmol) was added followed by benzylsulfonyl chloride, 2-Phenylethanesulfonyl chloride, benzene sulfonyl chloride, benzoyl chloride or phenylacetyl chloride (1.5mmol), and the mixture was stirred overnight at room temperature. The reaction was filtered, concentrated and solved by EA (20mL), then washed with ethyl acetate (3¡Á15mL). The organic was combined and was dried over Na2SO4. After filtration, the filtrate was removed in vacuo. The residue was purified by silica gel column chromatography to give 2b-12b, 16b-17b.

226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Article; Cao, Zhonglian; Fu, Wei; Ma, Xiaojun; Sun, Nannan; Wang, Yonghui; Xu, Jun; Zhou, Kaifeng; Zhu, Chen; European Journal of Medicinal Chemistry; vol. 187; (2020);,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,226942-29-6

A mixture of4-chloro-benzo[4,5]furo[3 ,2-d]pyrimidine (1.06 g, 5.19 mmol), 6-bromo- 1,2,3,4-tetrahydroisoquinoline (1.0 g, 4.7 mmol), potassium carbonate (1.95 g, 14.1 mmol) and sodium iodide (0.71 g, 4.7 mmol) in dioxane (50 mL) was heated at 90 C for 6 hrs. The mixture was diluted with EtOAc and washed with water, brine, dried over Na2SO4 and concentrated. The residue was purified by recrystallization with EtOAc to give 4-(6- bromo-3 ,4-dihydroisoquinolin-2( 1H)-yl)benzofuro[3 ,2-d]pyrimidine (1.2 g, 3.16 mmol,66.9 % yield). LCMS (M+H): 379.90, 381.90.

As the paragraph descriping shows that 226942-29-6 is playing an increasingly important role.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; EASTMAN, Kyle J.; KADOW, John F.; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PATEL, Manoj; SIVAPRAKASAM, Prasanna; TU, Yong; (275 pag.)WO2017/25915; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,226942-29-6

General procedure: Amine (0.25 mmol), and bromide (0.25 mmol) were taken up in acetonitrile (0.3 mL) in a conical vial equipped with a stirrer bar. Potassium carbonate (0.5 mmol) was added followed by potassium iodide (10 mol%) if required. The vial was sealed with a screwcap and the reaction was stirred at 40 C until thin layer chromatography (TLC) indicated complete consumption of the starting materials. A precipitate was formed during the reaction which was removed by filtration and the filtrate concentrated under reduced pressure. The residue was purified by flash column chromatography and sent to the Netherlands Cancer Institute (NKI) for biological testing.

226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Article; Milne, Kirsty; Sun, Jianhui; Zaal, Esther A.; Mowat, Jenna; Celie, Patrick H.N.; Fish, Alexander; Berkers, Celia R.; Forlani, Giuseppe; Loayza-Puch, Fabricio; Jamieson, Craig; Agami, Reuven; Bioorganic and Medicinal Chemistry Letters; vol. 29; 18; (2019); p. 2626 – 2631;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of 6-bromo-l,2,3,4-tetrahydroisoquinoline (100 mg, 0.472 mmol) and triethylamine (180 mu, 1.291 mmol) in anhydrous NMP (2.5 mL) was added to 2,4- dichloro-6-mophiholino-l,3,5-triazine (100 mg, 0.425 mmol). The reaction was flushed briefly with nitrogen, capped, stirred at room temp for 30 min at room temp, followed by heating at 80 C for 1 h. The crude reaction was purified via reverse phase Prep HPLC to afford 4-(4-(6-bromo-3,4-dihydroisoquinolin-2( lH)-yl)-6-chloro- l,3,5-triazin-2- yl)morpholine, 150 mg (86%). LCMS (M+l) = 410.1, 412.1. NuMuRhonu (500 MHz, (0186) DMSO-de) delta 7.48 – 7.35 (m, 2H), 7.24 (br dd, J=l 1.8, 8.3 Hz, 1H), 4.79 (br d, J=17.4 Hz, 2H), 3.90 (dt, J=14.6, 5.9 Hz, 2H), 3.76 (br s, 2H), 3.71 – 3.58 (m, 6H), 2.86 (br d, J=6.1 Hz, 2H).

226942-29-6, 226942-29-6 6-Bromo-1,2,3,4-tetrahydroisoquinoline 15885183, atetrahydroisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.226942-29-6,6-Bromo-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,226942-29-6

A mixture of 6-bromo-1,2,3,4-tetrahydroisoquinoline (800 mg, 3.8 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (1051 mg, 4.5 mmol) and potassium carbonate (1043 mg, 7.5 mmol) in NMP (10 mL) was stirred at 40 oC for 18 h. The reaction mixture was filtered and the filtrate was reduced in vacuo. The residue was purified by silica column chromatography eluting with 2% EtOAc in Pet. Ether to afford 6-bromo-2-(2,2,2-trifluoroethyl)-3,4-dihydro-1H-isoquinoline (800 mg, 2.72 mmol, 72% yield) as a white solid.1H NMR (400 MHz, DMSO-d6) delta 7.36- 7.26 (m, 2H), 7.03 (d, J = 8.1 Hz, 1H), 3.79- 3.74 (m, 2H), 3.38- 3.28 (m, 2H), 2.90 (m, 2H), 2.82 (m, 2H).

The synthetic route of 226942-29-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; REDX PHARMA PLC; JONES, Clifford, D.; BUNYARD, Peter; PITT, Gary; BYRNE, Liam; PESNOT, Thomas; GUISOT, Nicolas, E.S.; (318 pag.)WO2019/145729; (2019); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem

226942-29-6, 6-Bromo-1,2,3,4-tetrahydroisoquinoline is a tetrahydroisoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a dry microwave vial under nitrogen was added 2-(l- (2-chloropyrimidin-4-yl)piperidin-4-yl)propan-2-ol (540 mg, 2.111 mmol), 6-bromo- 1,2,3,4-tetrahydroisoquinoline (570 mg, 2.69 mmol) and anhydrous NMP (12 mL). The reaction was flushed with argon, treated with N,N-diisopropylethylamine (1.11 mL, 6.36 mmol), capped and heated in a microwave reactor at 160 C for 4 h. The solvent was removed under a gentle stream of niotrogen and the crude material was purified via silica gel chromatography (40g SiCh column, dichloromethane: ethyl acetate 100:0 -> 0: 100) to afford 2-(l-(2-(6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)pyrimidin-4-yl)piperidin-4- yl)propan-2-ol, 2.0 methyl-2-pyrrolidinone, 642.2 mg (48%). LCMS (M+l) = 431.2 and 433.1.

226942-29-6, The synthetic route of 226942-29-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BOWSHER, Michael S.; DESKUS, Jeffrey; EASTMAN, Kyle J.; GILLIS, Eric P; FRENNESSON, David B; IWUAGWU, Christiana; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M; SAULNIER, Mark G; SIVAPRAKASAM, Prasanna; (220 pag.)WO2018/127801; (2018); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem